Last reviewed · How we verify
NCT04588077
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Phase 4 trial testing Heplisav-B Injectable Product, 2-dose regimen in Hepatitis B in 200 participants. Currently enrolling.
1 December 2028
Quick facts
| Lead sponsor | Mercy Medical Center |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 200 |
| Start date | 14 September 2020 |
| Primary completion | 1 December 2028 |
| Estimated completion | 1 December 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Heplisav-B Injectable Product, 2-dose regimen — full drug profile →
- Heplisav-B Injectable Product, 3-dose regimen — full drug profile →
Conditions studied
- Hepatitis B — all drugs for Hepatitis B →
- Cirrhosis, Liver — all drugs for Cirrhosis, Liver →
- Chronic Liver Disease — all drugs for Chronic Liver Disease →
Sponsor
Mercy Medical Center
Who can join
18 and older, any sex, with Hepatitis B or Cirrhosis, Liver. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04588077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatitis B
Currently open trials in the same condition.
- NCT04843852 — TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B · Phase 1 · recruiting
- NCT07168356 — A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease · Phase 1 · recruiting
- NCT06947356 — Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads · NA · recruiting
- NCT06537414 — A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living Wit · Phase 2 · active not recruiting
- NCT06623071 — Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96/384 · recruiting
Other Mercy Medical Center trials
Trials by the same sponsor.
- NCT06750731 — Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease · recruiting
- NCT03846609 — Evaluation of a Double Balloon Interventional Platform (DiLumen) for Complex Colonic ESD · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04588077 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mercy Medical Center
- Last refreshed: 19 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04588077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing